201 related articles for article (PubMed ID: 36469536)
1. Selective TYK2 Inhibition in the Treatment of Moderate to Severe Chronic Plaque Psoriasis.
Gooderham MJ; Hong HC; Litvinov IV
Skin Therapy Lett; 2022 Nov; 27(6):1-5. PubMed ID: 36469536
[TBL] [Abstract][Full Text] [Related]
2. Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Lebwohl M; Warren RB; Sofen H; Imafuku S; Paul C; Szepietowski JC; Spelman L; Passeron T; Vritzali E; Napoli A; Kisa RM; Buck A; Banerjee S; Thaçi D; Blauvelt A
Br J Dermatol; 2024 Apr; 190(5):668-679. PubMed ID: 38226713
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of the selective TYK2 inhibitor, deucravacitinib, in Japanese patients with moderate to severe plaque psoriasis: Subgroup analysis of a randomized, double-blind, placebo-controlled, global phase 3 trial.
Imafuku S; Tada Y; Hippeli L; Banerjee S; Morita A; Ohtsuki M
J Dermatol; 2023 May; 50(5):588-595. PubMed ID: 36882942
[TBL] [Abstract][Full Text] [Related]
4. Deucravacitinib: The First FDA-Approved Oral TYK2 Inhibitor for Moderate to Severe Plaque Psoriasis.
Truong TM; Pathak GN; Singal A; Taranto V; Rao BK
Ann Pharmacother; 2024 Apr; 58(4):416-427. PubMed ID: 37341177
[TBL] [Abstract][Full Text] [Related]
5. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, phase 3 Program fOr Evaluation of TYK2 inhibitor psoriasis second trial.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
J Am Acad Dermatol; 2023 Jan; 88(1):40-51. PubMed ID: 36115523
[TBL] [Abstract][Full Text] [Related]
6. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial.
Armstrong AW; Gooderham M; Warren RB; Papp KA; Strober B; Thaçi D; Morita A; Szepietowski JC; Imafuku S; Colston E; Throup J; Kundu S; Schoenfeld S; Linaberry M; Banerjee S; Blauvelt A
J Am Acad Dermatol; 2023 Jan; 88(1):29-39. PubMed ID: 35820547
[TBL] [Abstract][Full Text] [Related]
7. Deucravacitinib for the Treatment of Psoriatic Disease.
Lé AM; Puig L; Torres T
Am J Clin Dermatol; 2022 Nov; 23(6):813-822. PubMed ID: 35960487
[TBL] [Abstract][Full Text] [Related]
8. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, in Japanese patients with moderate to severe plaque, erythrodermic, or generalized pustular psoriasis: Efficacy and safety results from an open-label, phase 3 trial.
Imafuku S; Okubo Y; Tada Y; Ohtsuki M; Colston E; Napoli A; Shao Y; Banerjee S; Morita A
J Dermatol; 2024 Mar; 51(3):365-379. PubMed ID: 38268101
[TBL] [Abstract][Full Text] [Related]
9. Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.
Chimalakonda A; Burke J; Cheng L; Catlett I; Tagen M; Zhao Q; Patel A; Shen J; Girgis IG; Banerjee S; Throup J
Dermatol Ther (Heidelb); 2021 Oct; 11(5):1763-1776. PubMed ID: 34471993
[TBL] [Abstract][Full Text] [Related]
10. Oral small-molecule tyrosine kinase 2 and phosphodiesterase 4 inhibitors in plaque psoriasis: a network meta-analysis.
Xu Y; Li Z; Wu S; Guo L; Jiang X
Front Immunol; 2023; 14():1180170. PubMed ID: 37334353
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of tyrosine kinase 2 inhibitor deucravacitinib in the treatment of plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Liu J; Liu W; Lin F; Shi N
Front Med (Lausanne); 2023; 10():1264667. PubMed ID: 37841017
[TBL] [Abstract][Full Text] [Related]
12. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
Blauvelt A; Rich P; Sofen H; Strober B; Merola JF; Lebwohl M; Morita A; Szepietowski JC; Lambert J; Hippeli L; Colston E; Balagula E; Banerjee S; Thaçi D
J Am Acad Dermatol; 2024 Apr; 90(4):775-782. PubMed ID: 38122848
[TBL] [Abstract][Full Text] [Related]
13. Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
Strober B; Blauvelt A; Warren RB; Papp KA; Armstrong AW; Gordon KB; Morita A; Alexis AF; Lebwohl M; Foley P; Kisa RM; Colston E; Wang T; Banerjee S; Thaçi D
J Eur Acad Dermatol Venereol; 2024 Mar; ():. PubMed ID: 38451052
[TBL] [Abstract][Full Text] [Related]
14. Deucravacitinib in the treatment of psoriasis.
Estevinho T; Lé AM; Torres T
J Dermatolog Treat; 2023 Dec; 34(1):2154122. PubMed ID: 36453809
[TBL] [Abstract][Full Text] [Related]
15. Clinical Utility of Deucravacitinib for the Management of Moderate to Severe Plaque Psoriasis.
Jin JQ; Spencer RK; Reddy V; Bhutani T; Liao W
Ther Clin Risk Manag; 2023; 19():413-423. PubMed ID: 37223005
[TBL] [Abstract][Full Text] [Related]
16. Treatment of plaque psoriasis with deucravacitinib (POETYK PSO-2 study): a plain language summary.
Strober B; Thaçi D; Sofen H; Kircik L; Gordon KB; Foley P; Rich P; Paul C; Bagel J; Colston E; Throup J; Kundu S; Sekaran C; Linaberry M; Banerjee S; Papp KA
Immunotherapy; 2023 Aug; 15(11):787-797. PubMed ID: 37150956
[TBL] [Abstract][Full Text] [Related]
17. Deucravacitinib, a selective tyrosine kinase 2 inhibitor, for the treatment of moderate-to-severe plaque psoriasis.
Galluzzo M; Vellucci L; Marcelli L; Paganini C; Bianchi L; Talamonti M
Expert Opin Pharmacother; 2023 Jun; 24(9):981-988. PubMed ID: 37147879
[TBL] [Abstract][Full Text] [Related]
18. Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis.
Armstrong AW; Park SH; Patel V; Hogan M; Wang WJ; Davidson D; Chirikov V
Dermatol Ther (Heidelb); 2023 Nov; 13(11):2589-2603. PubMed ID: 37525000
[TBL] [Abstract][Full Text] [Related]
19. Clinical Implications of Targeting the JAK-STAT Pathway in Psoriatic Disease: Emphasis on the TYK2 Pathway.
Loo WJ; Turchin I; Prajapati VH; Gooderham MJ; Grewal P; Hong CH; Sauder M; Vender RB; Maari C; Papp KA
J Cutan Med Surg; 2023; 27(1_suppl):3S-24S. PubMed ID: 36519621
[TBL] [Abstract][Full Text] [Related]
20. Tyrosine kinase 2 and Janus kinase‒signal transducer and activator of transcription signaling and inhibition in plaque psoriasis.
Krueger JG; McInnes IB; Blauvelt A
J Am Acad Dermatol; 2022 Jan; 86(1):148-157. PubMed ID: 34224773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]